Clinical Trials Logo

Disease clinical trials

View clinical trials related to Disease.

Filter by:

NCT ID: NCT00667745 Completed - Bipolar Disorder Clinical Trials

Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder

LiTMUS
Start date: April 2008
Phase: Phase 4
Study type: Interventional

This study evaluated whether lithium included as part of optimized medication treatment improved overall level of illness, symptoms of mania and depression, and quality of life in people with bipolar disorder.

NCT ID: NCT00667563 Completed - Cervical Cancer Clinical Trials

Vaccine Therapy in Preventing HPV in HIV-Positive Women in India

Start date: August 2009
Phase: Phase 1
Study type: Interventional

RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer. PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well it works in preventing cervical cancer in women in India with HIV-1 infection.

NCT ID: NCT00666211 Completed - Pain Clinical Trials

Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain

Start date: May 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: An Opioid Titration Order Sheet that allows healthcare providers to adjust the dose and schedule of pain medication may help improve pain treatment for patients with cancer. It is not yet known whether the use of an Opioid Titration Order Sheet is more effective than standard care in treating pain caused by cancer. PURPOSE: This randomized phase III trial is studying an Opioid Titration Order Sheet to see how well it works compared with standard care in treating patients with cancer pain.

NCT ID: NCT00665444 Terminated - Metabolic Syndrome Clinical Trials

Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder

Start date: April 2008
Phase: N/A
Study type: Interventional

The proposed study is a non-randomized, open label trial that will examine the potential to reduce metabolic risk factors in patients with bipolar I disorder and improve psychiatric and functional outcomes. To accomplish our objective, we plan to conduct a 5-month intervention of 50 obese or overweight adults diagnosed with bipolar disorder. The study will be divided in three steps: Screening, Baseline Period (cross taper to aripiprazole, up to 2 months in duration), Months 1-3 (continued aripiprazole treatment). Subjects will be assessed and meet with their study psychiatrist at least bi-monthly throughout their participation, more frequently when clinically necessary (e.g. during medication tapering or if manic/depressive symptoms emerge). Brief clinical assessments will be conducted at each visit. More thorough assessments will be conducted at Baseline, Week 2, and Month 3.

NCT ID: NCT00664976 Completed - Bipolar Disorder Clinical Trials

Treatment Resistant Depression in Bipolar Disorder - A Randomized Controlled Trial of Electroconvulsive Therapy

Start date: April 2008
Phase: N/A
Study type: Interventional

This project is a randomized controlled trial of electroconvulsive therapy (ECT) compared to treatment as usual (TAU) in the treatment of treatment resistant depression (TRD) in bipolar disorder. The purpose of the trial is to document the effect size, relative effect size and adverse effects of ECT in this condition. A specific purpose is to gain more knowledge about the effect on cognitive function.

NCT ID: NCT00662584 Completed - Clinical trials for Generalized Anxiety Disorder

Repetitive Magnetic Transcranial Stimulation (rTMS) in the Treatment of Generalized Anxiety Disorder (GAD)

Start date: August 2006
Phase: Phase 3
Study type: Interventional

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive method that holds promise for treating several psychiatric disorders. Yet the most effective location and parameters for treatment need more exploration. Also, whether rTMS is an effective treatment for individuals with a DSM-IV diagnosis of Generalized Anxiety Disorder (GAD) has not been empirically tested. The goal of this pilot study is to evaluate whether fMRI guided rTMS is effective in reducing symptoms of GAD.

NCT ID: NCT00662259 Completed - Clinical trials for Generalized Anxiety Disorder

Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder

GAD
Start date: April 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to find out how an anti-anxiety drug or placebo affects the activity of your brain when you are at rest and when you are viewing emotional material, such as, emotional faces and pictures.

NCT ID: NCT00661869 Completed - Schizophrenia Clinical Trials

Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness

Wellness
Start date: September 2006
Phase: N/A
Study type: Interventional

Obesity is increasing at an alarming rate in patients with schizophrenia, possibly in association with the increased use of atypical antipsychotics. In order to address the weight and metabolic syndrome issues, Manhattan Psychiatric Center (MPC) has implemented the Solutions for Wellness and Team Solutions Program. This program is designed to create a supportive, educational and monitoring environment to stabilize both the psychiatric and medical conditions and to prepare patients for independent management of their psychiatric and physical health condition in the community.

NCT ID: NCT00657787 Active, not recruiting - Clinical trials for Stress Disorders, Post-Traumatic

Development of a Post-Traumatic Stress Disorder (PTSD) Population Registry for Veterans

Start date: September 2008
Phase:
Study type: Observational

The overall objective of this project is to develop the first longitudinal registry of combat-exposed men and women with PTSD. This registry will provide essential data on the natural history, including progression and remission, and outcomes associated with PTSD in military service men and women who have utilized the Department of Veterans Affairs (VA) health care system. Additional goals of this project are to determine risk factors for PTSD among combat-exposed service men and women (by incorporating a combat-exposed non-PTSD group of veterans into analyses), and to assess the joint effects of combat exposure and PTSD on a broad range of outcome measures (by incorporating a non-combat-exposed group of veterans into analyses). Thus, the registry will allow an evaluation of current theoretical models of symptom development and progression in a large sample of service men and women who utilize the VA medical system. In addition to the PTSD registry, we will collect information on two comparison groups of OIF/OEF-era veterans to conduct nested case control studies within the general VA health care utilization database. First, a comparison group of combat veterans who are high utilizers of VA medical care, but who have not received a diagnosis of PTSD will be identified. This group will be used in analyses to identify risk factors for PTSD. Additionally, the rate of PTSD symptoms will be evaluated in this comparison group to estimate the prevalence of missed PTSD diagnoses among combat veterans with high rates of service utilization, and the resulting impact on utilization and outcomes. A second comparison group will consist of veterans with similar service record and demographic backgrounds, who were not deployed to the OIF/OEF war zones. Thus, the proposed project will create a PTSD registry from the VA database to assess the natural history and progression of PTSD in combat veterans from OIF/OEF and also to conduct case-control studies nested within the VA database. The case-control comparisons will be used to evaluate key hypotheses related to the specific aims of the overall project.

NCT ID: NCT00655226 Terminated - Depression Clinical Trials

Prevention of Depression in HIV/HCV Co-infected Substance Abuse Patients

Start date: March 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is effective in the prevention of depression during interferon and ribavirin treatment for hepatitis C infection.